Clinical trials: Relapse Remitting Multiple Sclerosis
Gut Microbiome, Gastrointestinal Microbiome
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.
- Conditions
- Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder
- Trial name
- NCT04031469
- Testing
- There is no intervention in this study
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- ProgenaBiome
Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis
Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis
Idiopathic inflammatory disorders of the central nervous system include various disorders of which multiple sclerosis is the most common.
- Conditions
- Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis, Controls, Multiple Sclerosis
- Trial name
- AMIS (NCT04201470)
- Testing
- Blood withdrawal, MRI, Neurologic / neuropsychologic tests - Patients
- Where
- France
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Multiple Sclerosis, Relapsing-Remitting, Optic Neuritis
Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis
Multiple sclerosis (MS) affects approximately 2.3 million patients worldwide, with a global median prevalence of 33 per 100,000. MS is diagnosed at an average of 30 years and affects twice as many women as men.
- Trial name
- NCT03401879
- Testing
- Dynamic Vessel Analyzer (DVA), Fourier Domain Doppler Optical Coherence Tomography (FDOCT), Optical coherence tomography (OCT)
- Where
- Austria
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Multiple Sclerosis, Relapsing-Remitting
Examining Effects of Tysabri on Cognitive Fatigue Using fMRI
The purpose of this research study is to investigate the effectiveness of Tysabri on cognitive fatigue in persons with Relapsing-Remitting Multiple Sclerosis (RRMS).
- Trial name
- NCT04565431
- Testing
- Tysabri
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Kessler Foundation
Multiple Sclerosis
PET Study in Multiple Sclerosis
While both conventional and advanced MRI techniques offer important insights into MS pathophysiology, important aspects of this inflammatory disorder are undetectable with existing MRI technology.
- Trial name
- NCT03787446
- Where
- Canada
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Multiple Sclerosis
Gene Expression Profiles in Multiple Sclerosis (MS)
The purpose of this study is to test differences in RNA levels between Multiple Sclerosis (MS) patients and normal subjects. RNA provides a "message" from genes altered in diseases.
- Trial name
- NCT00704834
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Multiple Sclerosis, Acute Relapsing, Multiple Sclerosis
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Multiple Sclerosis is a chronic autoimmune disease associated with inflammatory response harmful for the Central Nervous System.
- Trial name
- 5-HTSEP (NCT04546698)
- Testing
- blood sampling
- Where
- France
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Régional d'Orléans
Relapse Remitting Multiple Sclerosis
Early Versus Delayed Start of Ocrevus Zunovo for Relapsing Multiple Sclerosis
This study will compare starting Ocrevus Zunovo soon after an active episode of relapsing multiple sclerosis (MS) with starting it later.
- Trial name
- STAT (NCT07878923)
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Oklahoma Medical Research Foundation
Relapsing Remitting Multiple Sclerosis
High Dose Oral Versus Intramuscular Vitamin D3 Supplementation In Multiple Sclerosis Patients
This study aimed to evaluate oral and injectable routes in treatment of hypovitaminosis D in multiple sclerosis (MS) patients. The investigators aimed to assess the efficacy of each method, using the same Mega dose of 600 000 IU…
- Trial name
- NCT02696590
- Testing
- Vitamin D3
- Where
- Iran
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Isfahan University of Medical Sciences
Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis
PET with [18F]Flumazenil As an Index of Neurodegeneration in MS
Beyond white matter pathology, grey matter damage is considered as a key player in disability onset and progression in Multiple Sclerosis (MS).
- Trial name
- FLUMA-SEP-T (NCT03825601)
- Testing
- PET with [11C]Flumazenil
- Where
- France
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Multiple Sclerosis
Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis
The purpose of this study is to determine whether glatiramer acetate (Copaxone) will induce anti-inflammatory type II monocyte development during treatment of MS, and if these antigen presenting cells (APC) will promote Th2 and…
- Trial name
- NCT00819195
- Testing
- Glatiramer acetate
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Multiple Sclerosis
Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients
The purpose of this study is to evaluate the feasibility of [18F]Florbetapir positron emission tomography (PET) for assessment of demyelination in the patients with relapsing remitting multiple sclerosis.
- Trial name
- NCT01767493
- Testing
- [18F]Florbetapir PET imaging
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Relapsing-Remitting Multiple Sclerosis
Assessment of Attentional and Executive Disorders in Multiple Sclerosis Using Techniques of Virtual Reality
Since many years cognitive disorders are a main topic of clinical research in Multiple Sclerosis (MS) as there could be observed early on in the disease and could induce with time in patients significant socio-professional…
- Trial name
- SEPREV (NCT01805336)
- Testing
- Assessment of attentional functions by traditional tests, Assessment of attentional functions by virtual reality tests, Assessment of executive functions by traditional tests
- Where
- 2 sites in France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Caen
Multiple Sclerosis, Covid19
MS Relapses During COVID-19 Pandemic
Throughout the COVID-19 pandemic, and to our knowledge there have been no studies looking systematically at the occurrence of MS relapses and their subsequent management, during the peak of the first wave of the pandemic.
- Conditions
- Multiple Sclerosis, Covid19, Relapsing Remitting Multiple Sclerosis
- Trial name
- NCT04858763
- Testing
- No Intervention
- Where
- United Kingdom
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Nottingham University Hospitals NHS Trust
Relapsing-Remitting Multiple Sclerosis
fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls
Impaired short term memory, attention and concentration lapses, and slower processing of information occur in up to 40-65% of patients with Multiple Sclerosis (MS).
- Trial name
- NCT00391352
- Testing
- IFN-β-1a (Rebif®)
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Waukesha Memorial Hospital
Multiple Sclerosis, Relapsing-Remitting
Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI
The purpose of this research study is to investigate the effectiveness of MS Disease modifying medications on cognitive fatigue in persons with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- NCT04448977
- Testing
- Ocrevus
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Kessler Foundation
Relapsing-remitting Multiple Sclerosis
Mass Balance Study of MT-1303
The purpose of this study is to investigate the absorption, metabolism and excretion of MT-1303 in healthy subjects.
- Trial name
- NCT02293967
- Testing
- MT-1303
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Multiple Sclerosis, Relapsing-Remitting
Physical Activity, Sedentary Behaviour and Cardiometabolic Health in Multiple Sclerosis
This study evaluates the association between sedentary behaviour, physical activity, and the cardiometabolic health of Multiple Sclerosis via several cardiovascular, metabolic and anthropometric parameters.
- Trial name
- NCT05752630
- Where
- Belgium
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Hasselt University
Relapsing-remitting Multiple Sclerosis
Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis
There are two standard and a few second line treatments for RRMS. Since the disease cannot be cured by these existing treatments and all treatment options have significant limitations, there is the need to develop new treatment…
- Trial name
- RESI (NCT02364986)
- Testing
- Rebif®, Avonex
- Where
- 2 sites in Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- PD Dr. Marcus Müller
Multiple Sclerosis, Relapsing-remitting
Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health
This is a pilot study of oral vitamin D supplementation to determine if patients with Multiple Sclerosis (MS) and healthy individuals attain a similar increase in serum 25-hydroxyvitamin D levels.
- Trial name
- NCT01667796
- Testing
- Vitamin D3
- Where
- 2 sites in United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University